- (866) 704-3389
- |
- Home
- |
- Help
- |
- Cart
-
- Welcome Log In
Hoover's is Beta Testing our Industries section.
Biotechnology Research Equipment Industry News
Need More Information On This Industry? |
See It All Now! Free Trial866-704-3389 |
Biotechnology Research Equipment Industry News
Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity (6:00:00am Sat Nov. 7, 2009 CDT)
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Early recognition of symptoms such as fatigue and nausea, which occur frequently before an acute HAE attack, can provide patients with up to 24 hours to initiate treatment before further onset of the attack. ...
Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care (6:00:00am Sat Nov. 7, 2009 CDT)
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients conducted in parallel with the ongoing, prospective, open label International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 2) for C1-INH concentrate. Of the patients surveyed, 98.3 percent reported satisfaction with the treatment, with 37 percent responding that without C1-INH they would have sought emergency treatment and 43 percent would have deferred any medical therapy. ...
U.S. Census Bureau Daily Feature for Nov. 7 (11:01:00pm Fri Nov. 6, 2009 CDT)
WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ -- Following is the daily "Profile America" feature from the U.S. Census Bureau: ...
ATR: Obama Lied, His Tax Pledge Died (6:31:00pm Fri Nov. 6, 2009 CDT)
Obama endorses House health bill loaded with pledge-breaking tax hikes ...
SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results (6:10:00pm Fri Nov. 6, 2009 CDT)
BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and nine months ended September 30, 2009. ...
Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 (3:05:00pm Fri Nov. 6, 2009 CDT)
DURHAM, N.C., Nov. 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that a previously approved reverse split of its common stock will take effect at the start of trading on Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted basis. Oxygen Biotherapeutics, Inc. shares will trade under the new symbol OXBT. The stock also will have a new CUSIP number, 69207P 20 9, when the split becomes effective. ...
Watson to Present at Credit Suisse Healthcare Conference (3:00:00pm Fri Nov. 6, 2009 CDT)
MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, 2009 at 12:00 pm Eastern Standard Time. ...
Microbix Biosystems Re-files Annual Results With OSC (3:00:00pm Fri Nov. 6, 2009 CDT)
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering (2:43:00pm Fri Nov. 6, 2009 CDT)
SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company. ...
U.S. Mayors' Survey Shows Main Street America Still in Recession; Cities in Dire Need of Jobs (2:33:00pm Fri Nov. 6, 2009 CDT)
Budget Shortfalls in Most Cities Bad This Year; Worse Next Year ...
Frost & Sullivan: Strong Industry Growth in Hosted Contact Center Market in North America Despite Economic Meltdown (2:33:00pm Fri Nov. 6, 2009 CDT)
MOUNTAIN VIEW, Calif., Nov. 6 /PRNewswire/ -- Hosted contact center technology companies and application service providers continue to grow revenues in an increasingly competitive arena, despite poor economic conditions in North America. The primary reason is that the hosted model offers clients faced with reduced budgets and capital constraints an opportunity to deploy contact center on demand (CCOD) solutions with relative ease and speed. ...
A Majority of Greater Washington, DC Adults Say They Will Not Get H1N1 Vaccine (2:16:00pm Fri Nov. 6, 2009 CDT)
Board of Trade Concerned for Workforce Health and Economic Implications ...
Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th (2:09:00pm Fri Nov. 6, 2009 CDT)
AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on November 10th, 2009. ...
Scientists 'Unlock' Mystery of Creating Cultured Pearls from the Queen Conch (1:28:00pm Fri Nov. 6, 2009 CDT)
BOCA RATON, Fla., Nov. 6 /PRNewswire-USNewswire/ -- For more than 25 years, all attempts at culturing pearls from the queen conch (Strombus gigas) have been unsuccessful--until now. For the first time, novel and proprietary seeding techniques to produce beaded (nucleated) and non-beaded cultured pearls from the queen conch have been developed by scientists from Florida Atlantic University's Harbor Branch Oceanographic Institute (HBOI). With less than two years of research and experimentation, Drs. Hector Acosta-Salmon and Megan Davis, co-inventors, have produced more than 200 cultured pearls using the techniques they developed. Prior to this breakthrough, no high-quality queen conch pearl had been cultured. This discovery opens up a unique opportunity to introduce a new gem to the industry. This significant accomplishment is comparable to that of the Japanese in the 1920s when they commercially applied the original pearl culture techniques developed for pearl oysters. ...
Journal of Public Health Management & Practice Calls for Growth in Public Health Workforce (1:11:00pm Fri Nov. 6, 2009 CDT)
PHILADELPHIA, Nov. 6 /PRNewswire/ -- A recent special supplement to the Journal of Public Health Management calls attention to the country's pressing need for a larger and fully capable public health workforce. The supplement, written by the leading academic voices in public health and published by Lippincott Williams & Wilkins (LWW), also sheds light on the challenges the U.S. faces in adequately meeting public health needs. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy. ...
Register for a Free Trial Now!
Call (866) 704-3389 to get started, or fill out this form and we'll contact you to set up your custom trial. Calling from outside the US?